[ANTIAGGREGANT ACTIVITY OF A NEW TRICYCLIC BENZIMIDAZOLE DERIVATIVE]

Eksp Klin Farmakol. 2016 Aug;79(5):29-32.
[Article in Russian]

Abstract

The antiaggregant activity of a new benzimidazole derivative - 2,3,4,5-tetrahydro[1,3]diazepino[1,2-α]benzimidazole (DAB-15) has been investigated in vitro in comparison to reference drugs acetylsalicylic acid (ASA) and ticlid (ticlopidine) on the models of ASA, collagen, and epinephrine induced platelet aggregation in rabbits. It was established that DAB-15 exhibited dose-dependent antiaggregant activity. On the model of ASA-induced platelet aggregation, the effect of ADB-15 exceeded that of ASA and was slightly lower than that of ticlid. On the models of collagen, and epinephrine induced platelet aggregation, DAB-15 was reliably more active than the both reference drugs.

MeSH terms

  • Animals
  • Benzimidazoles* / chemical synthesis
  • Benzimidazoles* / chemistry
  • Benzimidazoles* / pharmacology
  • Blood Platelets / metabolism*
  • Blood Platelets / pathology
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors* / chemical synthesis
  • Platelet Aggregation Inhibitors* / chemistry
  • Platelet Aggregation Inhibitors* / pharmacology
  • Rabbits

Substances

  • Benzimidazoles
  • Platelet Aggregation Inhibitors